Volume 11, Issue 3 (Autumn 2014)
Sci J Iran Blood Transfus Organ 2014, 11(3): 190-196 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Poopak B, Taghdisi S, Heidari M, Fallah P, Khosravipour G, Bolouri S et al . Evaluation of common polymorphisms of CYP2C19 in Clopidogrel-treated patients. Sci J Iran Blood Transfus Organ 2014; 11 (3) :190-196
URL: http://bloodjournal.ir/article-1-782-en.html
URL: http://bloodjournal.ir/article-1-782-en.html
Full-Text [PDF 307 kb]
(2012 Downloads)
| Abstract (HTML) (7630 Views)
Evaluation of common polymorphisms of CYP2C19
in Clopidogrel-treated patients
Poopak B.1, Taghdisi Sh.1, Heidari M.1, Fallah P.2, Khosravipour G.3, Bolouri Sh.3, Golkar T.3
1School of Paramedicine, Tehran Medical Branch of Islamic Azad University, Tehran, Iran
2School of Medicine, Alborz University of Medical Sciences, Karaj, Iran
3Peyvand Clinical & Specialty Laboratory, Tehran, Iran
Abstract
Background and Objectives
Clopidogrel is one of the most commonly prescribed drugs to prevent ischemic events following coronary syndromes or stent placement. The objective of this study was to evaluate the prevalence of the cytochrome P450 (CYP450) 2C19 enzyme (CYP2C19) genotypes in the Iranian population.
Materials and Methods
CYP2C19 (*1/*2/*3) variants were analyzed using Polymerase Chain Reaction-Restriction Length Polymorphism (PCR–RFLP) assays in a representative sample of 154 Iranian patients with ischemic heart disease in Peyvand Laboratory.
Results
In this study, out of 154 Iranian patients the frequency rates of CYP2C19 *2 were 36 (23.4%) in heterozygous and 6 (3.9%) in homozygous forms; 112 (72.7%) patients had the normal genotype.
Conclusions
FDA recommendations are more useful to be practiced in our country than other countries. Physicians should identify patients and advise them to consider other antiplatelet medications or alternative dosing strategies in poor metabolizers.
Key words: clopidogrel, Genetic Polymorphism, CYP2C19٬ human, Ischemic Heart Disease
Received: 3 Sep 2013
Accepted: 3 Mar 2014
Correspondence: Poopak B., PhD of Hematology. Assistant Professor of School of Paramedicine, Tehran Medical Branch of Islamic Azad University.
P.O.Box: 19395-1495, Tehran, Iran. Tel: (+9821) 22257438; Fax : (+9821) 22257438
E-mail: bpoopak@yahoo.com
Full-Text: (2758 Views)
References :
with clopidogrel in acute coronary syndrome. Am J Cardiol. 2008; 101(8): 1088-93.
- Patrono C, Bachmann F, Baigent C, Bode C, De Caterina R, Charbonnier B, et al. Expert consensus document on the use of antiplatelet agents. Rev Esp Cardiol 2004; 57(10): 963-80. [Article in Spanish]
- Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288(19): 2411-20.
- Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol.2005; 45(8): 1157-64.
- Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Jukema JW, Huisman MV. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J 2007; 154(2): 221-31.
- Frere C, Cuisset T, Morange PE, Quilici J, Camoin-Jau L, Saut N, et al. Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment
with clopidogrel in acute coronary syndrome. Am J Cardiol. 2008; 101(8): 1088-93.
- Pereillo JM, Maftouh M, Andrieu A, Uzabiaga MF, Fedeli O, Savi P, et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 2002; 30(11): 1288-95.
- Giusti B, Gori AM, Marcucci R, Saracini C, Vestrini A, Abbate R. Determinants to optimize response to clopidogrel in acute coronary syndrome. Pharmgenomics Pers Med 2010; 3: 33-50.
- Subraja K, Dkhar SA, Priyadharsini R, Ravindra BK, Shewade DG, Satheesh S, et al. Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population. Eur J Clin Pharmacol 2013; 69(3): 415-22.
- Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006; 108(7): 2244-7.
- Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009; 302(8): 849-57.
- Sameer AE, Amany GM, Abdela AA, Fadel SA. CYP2C19 genotypes in a population of healthy volunteers and in children with hematological malignancies in Gaza Strip. Can J Clin Pharmacol 2009; 16(1): e156-62.
- Anichavezhi D, Chakradhara Rao US, Shewade DG, Krishnamoorthy R, Adithan C. Distribution of CYP2C19*17 allele and genotypes in an Indian population. J Clin Pharm Ther 2012; 37(3): 313-8.
- Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, et al. Genetic determinants of
response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360(4): 363-75. - Hulot JS, Collet JP, Silvain J, Pena A, Bellemain-Appaix A, Barthélémy O, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol 2010; 56(2): 134-43.
- Djaffar Jureidini I, Chamseddine N, Keleshian S, Naoufal R, Zahed L, Hakime N. Prevalence of CYP2C19 polymorphisms in the Lebanese population. Mol Biol Rep 2011; 38(8): 5449-52.
- Rogan PK, Svojanovsky S, Leeder JS. Information theory-based analysis of CYP2C19, CYP2D6 and CYP3A5 splicing mutations. Pharmacogenetics 2003; 13(4): 207-18.
|
||||
|
||||
Evaluation of common polymorphisms of CYP2C19
in Clopidogrel-treated patients
Poopak B.1, Taghdisi Sh.1, Heidari M.1, Fallah P.2, Khosravipour G.3, Bolouri Sh.3, Golkar T.3
1School of Paramedicine, Tehran Medical Branch of Islamic Azad University, Tehran, Iran
2School of Medicine, Alborz University of Medical Sciences, Karaj, Iran
3Peyvand Clinical & Specialty Laboratory, Tehran, Iran
Abstract
Background and Objectives
Clopidogrel is one of the most commonly prescribed drugs to prevent ischemic events following coronary syndromes or stent placement. The objective of this study was to evaluate the prevalence of the cytochrome P450 (CYP450) 2C19 enzyme (CYP2C19) genotypes in the Iranian population.
Materials and Methods
CYP2C19 (*1/*2/*3) variants were analyzed using Polymerase Chain Reaction-Restriction Length Polymorphism (PCR–RFLP) assays in a representative sample of 154 Iranian patients with ischemic heart disease in Peyvand Laboratory.
Results
In this study, out of 154 Iranian patients the frequency rates of CYP2C19 *2 were 36 (23.4%) in heterozygous and 6 (3.9%) in homozygous forms; 112 (72.7%) patients had the normal genotype.
Conclusions
FDA recommendations are more useful to be practiced in our country than other countries. Physicians should identify patients and advise them to consider other antiplatelet medications or alternative dosing strategies in poor metabolizers.
Key words: clopidogrel, Genetic Polymorphism, CYP2C19٬ human, Ischemic Heart Disease
Received: 3 Sep 2013
Accepted: 3 Mar 2014
Correspondence: Poopak B., PhD of Hematology. Assistant Professor of School of Paramedicine, Tehran Medical Branch of Islamic Azad University.
P.O.Box: 19395-1495, Tehran, Iran. Tel: (+9821) 22257438; Fax : (+9821) 22257438
E-mail: bpoopak@yahoo.com
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
